


Benserazide hydrochloride

12/19

ALTERNATE NAMES: DL-Serine 2-(2,3,4-Trihydroxybenzyl)hydrazide Hydrochloride; 2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide hydrochloride; 2-amino-3-hydroxy-N'-(2,3,4-trihydroxyphenyl)methylpropanehydrazide, hydrochloride

CATALOG #: B2963-100 100 mg
B2963-500 500 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₀H₁₆CIN₃O₅

MOLECULAR WEIGHT: 293.7

CAS NUMBER: 14919-77-8

APPEARANCE: A crystalline solid

PURITY: ≥95%

SOLUBILITY: ~16 mg/ml in DMSO
~20 mg/ml in DMF

DESCRIPTION: Benserazide is an inhibitor of aromatic L-amino acid decarboxylase (AADC), an enzyme that has dopamine decarboxylase activity. It blocks the conversion of L-DOPA to dopamine by AADC in the peripheral circulatory system. It causes an increase in the amount of L-DOPA reaching the central nervous system and so reduces the required dose. It is often combined with L-DOPA in patients with Parkinson's disease.

STORAGE TEMPERATURE: -20°C. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Soares-Da-Silva, P., Serrão, M.P., and Vieira-Coelho, M.A. Apical and basolateral uptake and intracellular fate of dopamine precursor L-dopa in LLC-PK1 cells. Am.J.Physiol. 274(2 Pt 2), F243-251 (1998).
2. Di Stefano, A., Dozio, P., and Cerasa, L.S. Antiparkinson prodrugs. Molecules 13(1), 46-68 (2008).
3. Shen, H., Kannari, K., Yamato, H., et al. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J.Exp.Med. 199(3), 149-159 (2003).

RELATED PRODUCTS:

Thioridazine Hydrochloride (Cat. No. B1581)
Chlorpromazine Hydrochloride (Cat. No. B1992)
Valbenazine (Cat. No. B2954)
Aripiprazole (Cat. No. B1186)
Bifeprunox (Cat. No. B2921)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**